Undetectable pre-surgery tumor DNA predicts better outcomes in bladder cancer patients

What is it about?

This study examines circulating tumor DNA (ctDNA) in patients undergoing radical cystectomy (RC) for bladder cancer. The research assessed recurrence-free survival (RFS) based on ctDNA status before and after surgery. Patients with undetectable ctDNA before RC had favorable outcomes, with 93% and 82% RFS at 12 and 18 months, respectively. The study also compared patients who maintained undetectable ctDNA status to those who converted from detectable to undetectable after surgery. Those with persistently undetectable ctDNA had significantly better RFS than the conversion group. The findings suggest that pre-RC ctDNA status could be valuable in treatment decision-making and potentially allow for de-escalation of treatment in some patients. The study recommends incorporating both pre-RC and post-RC (minimal residual disease window) ctDNA status in future clinical trials and treatment protocols.

Featured Image

Why is it important?

This research is significant because it investigates the use of circulating tumor DNA (ctDNA) as a biomarker for assessing recurrence-free survival (RFS) in patients with bladder cancer undergoing radical cystectomy (RC). Understanding the prognostic value of ctDNA status before and after surgery could lead to more personalized treatment strategies, potentially reducing unnecessary interventions for low-risk patients and identifying high-risk patients who may benefit from additional therapy. The study's findings contribute to the growing body of evidence supporting the use of liquid biopsies in cancer management, highlighting the importance of incorporating molecular markers alongside traditional pathological staging for improved clinical decision-making. Key Takeaways: 1. Prognostic Value: Patients with undetectable pre-RC ctDNA status demonstrated favorable oncological outcomes, with high recurrence-free survival rates at 12 and 18 months, suggesting that ctDNA status could be a valuable tool for risk stratification. 2. Conversion Dynamics: The study revealed that patients who converted from detectable to undetectable ctDNA status after RC had worse outcomes compared to those with persistently undetectable ctDNA, emphasizing the importance of considering both pre-RC and post-RC (MRD window) ctDNA status in clinical decision-making. 3. Treatment Implications: The findings suggest that pre-RC ctDNA status could potentially be used to guide treatment decisions, such as de-escalating treatment for low-risk patients or intensifying therapy for high-risk patients, highlighting the need for incorporating ctDNA analysis into clinical trials and treatment protocols.